Currently Viewing:
Newsroom
Currently Reading
Novartis Says CGRP Migraine Blocker Shows Good Results in Late-Stage Study
January 23, 2018 – Allison Inserro
VA Won't Research Medical Marijuana for Chronic Pain or PTSD Among Veterans
January 17, 2018 – Laura Joszt
PTSD Linked With Persistent Neck Pain, Disability Among Vehicle Crash Survivors
January 09, 2018 – Allison Inserro
Researchers Find Veterans Suffer From Dry Eye As a Comorbid Pain Condition
January 09, 2018 – Allison Inserro
Molecular Discovery Moves Scientists Closer to Designing Pain Relief Without Side Effects
January 04, 2018 – Allison Inserro
Studies Show Advantages of Topical Analgesics in Chronic Pain Management
January 02, 2018 – Allison Inserro
Study Suggests Screening Patients With Fibromyalgia Syndrome for ADHD
December 28, 2017 – Allison Inserro
Cellular Communication Discovery Could Pave Way for Improved Neuropathic Pain Treatment
December 24, 2017 – Allison Inserro
Rain and Pain Not Related, Harvard Researchers Say
December 13, 2017 – Allison Inserro

Novartis Says CGRP Migraine Blocker Shows Good Results in Late-Stage Study

Allison Inserro
Novartis' calcitonin gene-related peptide (CGRP) inhibitor for prevention of migraine, erenumab, showed positive results in a phase 3b study in episodic migraine patients who have failed multiple prior preventive treatments.
 
Novartis' calcitonin gene-related peptide (CGRP) inhibitor for prevention of migraine, erenumab, showed positive results in a phase 3b study in episodic migraine patients who have failed multiple prior preventive treatments.

Erenumab (AMG 334) achieved at least a 50% reduction of migraine days versus placebo, and all secondary endpoints, including:
  • reduction of monthly migraine days
  • reduction in days needing rescue medication
  • improvement in scores on the Migraine Physical Function Impact Diary (MPFID) tool
  • and 75% and 100% responder rates (number of patients experiencing at least a 75% or 100% reduction in monthly migraine days compared to placebo)


The monoclonal antibody is currently under FDA review. If approved, it will be administered once-monthly using a self-injection device. 

Novartis and Amgen will co-commercialize erenumab in the US. Amgen has exclusive commercialization rights to the drug in Japan and Novartis has exclusive rights to commercialize in the rest of the world.

The Institute for Clinical and Economic Review (ICER) is reviewing erenumab and other CGRPs for clinical effectiveness and value. The analysis is expected later this year.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up